DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category SMMT
Summit Therapeutics Inc
ASCO 2026 Investor Calendar: 25 Key Oncology Presentations, Dates, Times and Webcasts to Track
ASCO 2026 runs from May 29 to June 2, 2026 in Chicago and online. Regular abstract text was released before the meeting, while ASCO states that late-breaking abstracts, including plenary LBAs, are released at 7:00 AM CT / 8:00 AM ET on the day of their presentation. That timing matters because some of the most important market reactions may begin before the actual oral presentation if the abstract text contains enough clinical detail.
Summit Therapeutics ( $SMMT ): the HARMONi-3 selloff does not kill the story, but it changes the burden of proof
Summit Therapeutics is not a normal quarterly earnings story. The company has no commercial revenue profile to dissect in the usual way, no product-sales margin trend to model, and no near-term EPS narrative that matters more than its clinical and regulatory path. $SMMT is a concentrated bet on ivonescimab, also known as SMT112 in Summit’s licensed territories, a PD-1/VEGF bispecific antibody that has become one of the most closely watched potential challengers to the PD-1 oncology establishment.
Summit Therapeutics (SMMT): ELCC 2026 posters, stronger cash, and why retail is trying to rebuild the ivonescimab story
The latest Summit update does not magically erase the old debate around overall survival, but it does add new material that retail traders and long-form biotech readers can use to reframe the case: deeper intracranial data, quality-of-life support, a visible FDA date, and a balance sheet that gives the company room to keep pushing an unusually broad ivonescimab program.
SMMT Summit Therapeutics Inc
Summit Therapeutics Inc. (NASDAQ: SMMT) has effectively transformed itself into a single-asset, late-stage oncology company centered on ivonescimab (SMT112), a PD-1 × VEGF bispecific antibody licensed from Akeso in January 2023 (FY2024 PR). Ivonescimab is already approved in China (Akeso) and is now in a broad, global Phase III program led by Summit in NSCLC and colorectal cancer.
JPM Healthcare Conference 2026
The 44th Annual J.P. Morgan Healthcare Conference is widely considered the most influential healthcare investment meeting in the world. Often described as the “Super Bowl of Healthcare”, it brings together more than 8,000 participants, including C-suite executives, institutional investors, policymakers, analysts and media.
SMMT Summit Therapeutics Inc
Summit Therapeutics has transformed itself into a single-asset late-stage oncology story around ivonescimab, a PD-1 x VEGF bispecific licensed from Akeso and already approved in China.
SMMT Summit Therapeutics
ummit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical company focused on developing innovative oncology therapies. The primary pipeline is built around ivonescimab, a first-in-class bispecific antibody developed in partnership with Akeso Biopharma (China).
